SEC Form 4 · accession 0001613377-18-000024
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas K. Equels
Officer — Exec. Vice Chairman/CEO/Pres. · Director
Period of report
Oct 17, 2018
Accepted (ET)
Oct 19, 2018 · 12:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000946644
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to buy Common StockF1 | $0.22 | Oct 17, 2018 | A | 284,091 | A | Oct 17, 2018 | Oct 17, 2028 | Common Stock | 284,091 | 284,091 | D |
Explanation of responses
- F1This option is being issued to senior management in exchange for a voluntary 50% deferral in salary.